Event time: 事件时间：
Published: 文章发布：
Key Results
Actual vs Consensus
EPS: $0.87 vs $0.73 estimate, beat+18.4%.Revenue: $16.6B vs $15.9B estimate, beat+4.6%.Profitability and Cash Flow
Period: 2026 Q3 period ended 2026-09-27Revenue: $16.6B; YoY: -0.4%; QoQ: +10.3%Gross profit: $15.5B; Gross margin: 93.2%Operating income: $3.3B; Operating margin: 19.6%; YoY: -41.2%; QoQ: -8.1%Net income: $3.3B; GAAP diluted EPS: $0.57; YoY: -8.2%; QoQ: +1410.9%Operating cash flow: $5.4B; Capex: $573M; Free cash flow: $4.8BCash: $1.8B; Total debt: $62.7B; Net debt: $60.8BOfficial release: Pfizer Reports Strong Third-Quarter 2026 Results And Raises 2026 Guidance
核心结果
实际值与市场预期
EPS：$0.87 vs $0.73 预期，高于预期+18.4%。营收：$16.6B vs $15.9B 预期，高于预期+4.6%。财务指标
期间：2026 Q3（截至 2026-09-27）营收：$16.6B；同比：-0.4%；环比：+10.3%毛利润：$15.5B；毛利率：93.2%经营利润：$3.3B；经营利润率：19.6%；同比：-41.2%；环比：-8.1%净利润：$3.3B；GAAP 稀释 EPS：$0.57；同比：-8.2%；环比：+1410.9%经营现金流：$5.4B；资本开支：$573M；自由现金流：$4.8B现金：$1.8B；总债务：$62.7B；净债务：$60.8B
